Smoking Cessation — The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome
Citation(s)
Allen SS, Hatsukami D, Gorsline J Cholesterol changes in smoking cessation using the transdermal nicotine system. Transdermal Nicotine Study Group. Prev Med. 1994 Mar;23(2):190-6.
Arnaot MR Treating heart disease. Nicotine patches may not be safe. BMJ. 1995 Mar 11;310(6980):663-4.
Barnes PJ New concepts in chronic obstructive pulmonary disease. Annu Rev Med. 2003;54:113-29. Epub 2001 Dec 3. Review.
Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol. 1993 Oct;22(4):1159-67.
Benowitz NL Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med. 1988 Nov 17;319(20):1318-30. Review.
Cardiovascular Disease Surveillance Laboratory Centre for Disease Control, Statistics Canada 2002, Candian Institutes for Health Information (CIHI), 2002.
Gillum RF, Ingram DD, Makuc DM White blood cell count and stroke incidence and death. The NHANES I epidemiologic follow-up study. Am J Epidemiol. 1994 May 1;139(9):894-902.
Gourlay S The pros and cons of transdermal nicotine therapy. Med J Aust. 1994 Feb 7;160(3):152-9. Review.
Greenland S, Satterfield MH, Lanes SF A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf. 1998 Apr;18(4):297-308.
Grimm RH Jr, Neaton JD, Ludwig W Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA. 1985 Oct 11;254(14):1932-7.
Hansen PR Role of neutrophils in myocardial ischemia and reperfusion. Circulation. 1995 Mar 15;91(6):1872-85. Review.
Palmer KJ, Buckley MM, Faulds D Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs. 1992 Sep;44(3):498-529. Review.
Pickering TG, Schwartz JE, James GD Ambulatory blood pressure monitoring for evaluating the relationships between lifestyle, hypertension and cardiovascular risk. Clin Exp Pharmacol Physiol. 1995 Mar;22(3):226-31. Review.
Pierce JR Jr Stroke following application of a nicotine patch. Ann Pharmacother. 1994 Mar;28(3):402.
Rietbrock N, Kunkel S, Wörner W, Eyer P Oxygen-dissociation kinetics in the blood of smokers and non-smokers: interaction between oxygen and carbon monoxide at the hemoglobin molecule. Naunyn Schmiedebergs Arch Pharmacol. 1992 Jan;345(1):123-8.
Silagy C, Mant D, Fowler G, Lodge M Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 1994 Jan 15;343(8890):139-42.
Stapleton J Cigarette smoking prevalence, cessation and relapse. Stat Methods Med Res. 1998 Jun;7(2):187-203.
Tang JL, Law M, Wald N How effective is nicotine replacement therapy in helping people to stop smoking? BMJ. 1994 Jan 1;308(6920):21-6. Erratum in: BMJ 1994 Mar 5;308(6929):626.
Transdermal nicotine for smoking cessation Six-month results from two multicenter controlled clinical trials. Transdermal Nicotine Study Group. JAMA. 1991 Dec 11;266(22):3133-8.
Warner JG Jr, Little WC Myocardial infarction in a patient who smoked while wearing a nicotine patch. Ann Intern Med. 1994 Apr 15;120(8):695.
Wilson K, Gibson N, Willan A, Cook D Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med. 2000 Apr 10;160(7):939-44.
Zevin S, Benowitz NL Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999 Jun;36(6):425-38. Review.
Zevin S, Jacob P 3rd, Benowitz NL Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther. 1998 Jul;64(1):87-95.
The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome: The STADIA Pilot Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.